Disruptions in Amino Acid, Lipid Metabolism May Signal Tardive Dyskinesia
By Elana Gotkine HealthDay Reporter
THURSDAY, March 20, 2025 -- Disruptions in amino acid and lipid metabolism may be biomarkers of tardive dyskinesia (TD), according to a study published online Feb. 21 in Schizophrenia Bulletin.
Chenghao Lu, from the Mental Health Center of Tianjin Medical University in China, and colleagues explored biomarkers of TD through untargeted metabolomics for the early identification of TD in a study involving 84 patients with schizophrenia (SZ) with TD and 160 patients with SZ without TD. Fasting blood samples were collected from all patients; 699 metabolites were quantified and profiled.
The researchers found that 57 metabolites exhibited significant changes in TD, mainly involving amino acids and lipids. These changes mostly affected the phenylalanine, tyrosine, and tryptophan pathway and the phenylalanine metabolism pathway. Negative relations to the total abnormal involuntary movement scale score were seen for N-acetyl-L-phenylalanine and succinylcarnitine. Five differential metabolites had area under the curve (AUC) values greater than 0.7 for diagnosing TD, with a combined AUC of 0.817.
"These findings provide possible biomarkers for the diagnosis of TD, facilitating early recognition of TD," the authors write. "However, these preliminary results require validation in larger sample sizes and longitudinal studies."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-03-21 06:00
Read more

- IBD Activity May Increase Risk for Clostridioides Difficile Infection
- Dr. Oz Accused of Underpaying Medicare Taxes Ahead of Nomination Hearing
- GLP-1 Drugs Improve Outlook For Kidney Transplants
- New Clot-Busting Drug Quicker And As Effective In Treating Stroke
- FDA Makes Access to Clozapine Easier for Patients With Schizophrenia
- Few Nonsurgical Treatments Show Effectiveness for Low Back Pain
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions